ClinicalTrials.gg
RecruitingNCT06702085Updated Nov 22, 2024

Lifestyle Changes in Older Adults With Metabolic Syndrome and Tinnitus

An interventional study of Lifestyle Management in Tinnitus, Metabolic Syndrome X and Obesity, sponsored by Cairo University. Recruiting at 2 sites in Egypt. Open to participants aged 65 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-22.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Registered 10 months after the study started (first participant enrolled Jan 2024, registered Nov 2024).
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
65 Years to 75 Years
Sex
All
01

Study summary

The problem of tinnitus (subjective type) is prevalent in obese older adults with different diseases such as metabolic syndrome. The changes of lifestyle are very important to lose weight, improve tinnitus and metabolic syndrome

Read the detailed description

Sixty older adults (with metabolic syndrome with chronic subjective tinnitus) with obesity were selected in a equal random manner to be classified into the first group that administered changes in their lifestyle (exercise applied on treadmill and low caloric diet) for twelve successive weeks and second group that was not administered lifestyle changes

02

Conditions studied

  • Tinnitus
  • Metabolic Syndrome X
  • Obesity
  • Elderly
  • Weight Loss
03

In context

Tinnitus

446 studies on the registry are indexed under Tinnitus; 98 are open to participants now.

This study's planned enrollment of 60 is close to the median of 60 across 370 interventional studies indexed under Tinnitus.

Browse Tinnitus studies →

Lead sponsor

Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obese person (class one obesity)
  • patients with metabolic syndrome
  • patients with chronic subjective tinnitus (bilateral complaint from more than six months).
  • older adults aging 65 years and more
  • both sexes will be included

Exclusion criteria

Exclusion Criteria:

  • respiratory insult
  • cardiac insult
  • liver insult
  • kidney insult
  • lower limb insult
  • neurological insult
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    first group

    thirty older adults (with obesity, metabolic syndrome, and chronic subjective tinnitus) administered supervised changes in their lifestyle (walking exercise for 40 minutes applied on treadmill for three time per week and low caloric diet) for twelve weeks

    Behavioral: Lifestyle Management

  • No intervention
    second group

    thirty older adults (with obesity, metabolic syndrome, and chronic subjective tinnitus) served as control patients who did not receive any changes in their lifestyle

Interventions

  • BehavioralLifestyle Management

    patients administered supervised changes in their lifestyle (walking exercise for 40 minutes applied on treadmill for three time per week and low caloric diet) for twelve weeks

06

What researchers measure

Primary outcomes

  1. visual analogue scale of tinnitus severity

    it is scale (10 cm) that will assess severity of tinnitus

    Time frame: twelve weeks

Secondary outcomes

  1. visual analogue scale of tinnitus related discomfort

    it is a scale (10 cm) that will assess tinnitus related discomfort

    Time frame: twelve weeks

  2. tinnitus handicap inventory

    it is a questionnaire that will assess quality of life in tinnitus population

    Time frame: twelve weeks

  3. body mass index

    it will be assessed at morning after evacuation of bowel and bladder

    Time frame: twelve weeks

  4. waist circumference

    it will be measured at the level of umbilicus

    Time frame: twelve weeks

  5. triglycerides

    it will be measured in the serum

    Time frame: twelve weeks

  6. high density lipoprotein

    it will be assessed in the serum

    Time frame: twelve weeks

  7. systolic blood pressure

    it will be assessed by mercury sphygmomnameter

    Time frame: twelve weeks

  8. diastolic blood pressure

    it will be assessed by mercury sphygmomnameter

    Time frame: twelve weeks

  9. fasting blood glucose

    it will be measured in serum

    Time frame: twelve weeks

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2025, 12 months after the start.

Of 134 non-industry interventional studies with no phase under Tinnitus, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 12 months is below that.

Counting every sponsor, half of 153 studies reached it within 17 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2024
First posted
Nov 22, 2024
StartActual
Jan 1, 2024
Primary completionEst.
Jan 1, 2025
CompletionEst.
Jan 1, 2025
Last update
Nov 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06702085
Lead sponsor
Cairo University
Responsible party
Ali Mohamed Ali ismail (lecturer, Department of Physical Therapy for Cardiovascular/Respiratory Disorders and Geriatrics, Faculty of Physical Therapy, Cairo University, Cairo University) — Principal investigator
First posted
Nov 22, 2024
Start date
Jan 1, 2024
Primary completion
Jan 1, 2025 (estimated)
Completion
Jan 1, 2025 (estimated)
Last update
Nov 22, 2024

Study contacts

Ali MA Ismail, Lecturer
Contact
ali.mohamed@pt.cu.edu.eg
+201005154209
Ali MA Ismail, Lecturer
principal investigator · Cairo University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion